Buy Fresenius Stock in 2026: Share Price, Dividend and Analysis
Thinking about buying Fresenius stock? After three painful years of write-downs and simplification, the Bad Homburg-based healthcare group is back on track with sharply improved results. This page covers the share price, the accounts for the last three financial years, the dividend, strengths and risks, and how to buy the stock from France.
Fresenius Share Price
You can check the live share price with your broker or on the leading financial platforms; as the stock is quoted in euros, there are no currency conversion fees for euro-based investors. Before placing any order, take the time to reread our guide on how to buy shares.
To compare with other healthcare stocks, also see our analysis of Fonar stock.
Fresenius Stock Profile
| Company | Fresenius SE & Co. KGaA |
| Market | XETRA (Frankfurt), DAX index (checked on 10/27/2026) |
| Ticker / Symbol | FRE — FRE.DE line in euros |
| ISIN | DE0005785604 |
| Headquarters | Bad Homburg (Germany) |
| Sector | Healthcare: Kabi products (nutrition, generics, biosimilars), Helios hospitals |
| Trading currency | Euro (EUR) |
| Financial year-end | December 31 |
| PEA eligibility | Yes (German issuer, European Union) |
About Fresenius: Business and Restructuring
Two complementary healthcare businesses
Fresenius SE is the parent company of a group founded more than a century ago around a hospital pharmacy. Fresenius Kabi produces generic drugs, clinical nutrition, infusion devices and biosimilars sold worldwide; Fresenius Helios operates one of Germany’s leading private hospital and clinic groups, which also has a presence in Spain.
A radical simplification of the group
Since Michael Sen took over as CEO at the end of 2022, the structure has been slimmed down one divestment after another: dialysis (Fresenius Medical Care) is no longer consolidated and has become a simple financial stake, the Eugin fertility clinic chain has been sold, and Vamed’s problem businesses have been wound up. The group is now focused on Kabi and Helios.
A sought-after defensive profile
Healthcare, growing demand for care as Europe’s population ages, and essential products with little sensitivity to the economic cycle: this is the profile of a defensive large-cap stock that has regained the market’s favor after its rough patch.
Fresenius Results and Financial Data
Consolidated accounts for the last three financial years ended December 31:
| Indicator | FY 2023 | FY 2024 | FY 2025 | Year-on-year change |
|---|---|---|---|---|
| Revenue | €21.1bn | €22.0bn | €22.9bn | +4.2% |
| Net income | -€0.6bn | €0.5bn | €1.3bn | back to growth |
Amounts in billions of euros. Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data accessed on 10/27/2026.
The figures tell the story of a turnaround: a net loss of €0.6 billion in 2023 due to write-downs in dialysis and fertility, a return to profit in 2024, then net income nearly tripling in 2025, driven by growth at Kabi and the solidity of Helios. Revenue growth remains moderate (+4%), typical of a mature healthcare group.
Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →Fresenius Stock Dividend
After the difficult 2023 financial year, the dividend was maintained and then raised: €1.00 per share for 2024, then €1.05 for 2025 according to StockAnalysis data, for a yield of around 2% to 3%. This deliberate caution is consistent with the priority given to reducing debt.
The dividend is not the main argument for the stock: it is the rebuilding of earnings and the simplification of the group that underpin the investment case.
Should You Buy Fresenius Stock in 2026?
Strengths:
- Two solid healthcare businesses: Kabi growing worldwide, Helios the leading private hospital operator in Germany.
- Earnings recovery confirmed two years in a row, with a refocused and easier-to-read group.
- Defensive profile against the economic cycle, with exposure to an aging population.
Points to watch:
- Debt still significant after the years of expansion, despite asset sales.
- Constant pressure on hospital rates and healthcare product prices in Germany and Europe.
- Stake in Fresenius Medical Care, whose value depends on that company’s performance.
- The transformation plan is still being carried out: margins have yet to be rebuilt.
Fresenius is a large-cap healthcare stock that has become easier to read after its portfolio moves. It can be one of the best defensive stocks in a diversified portfolio, provided you accept an operational turnaround that is not yet complete.
Fundamental and Technical Analysis of Fresenius Stock
Fundamental analysis
Key indicators to watch: the operating margins of Kabi and Helios, organic revenue growth, net leverage and the divestment policy. The annual reports published by the group detail each segment’s contribution: check the latest reports before making any decision.
Technical analysis
The stock trades continuously on XETRA with good liquidity. The usual technical analysis reference points — moving averages, long-term support levels, earnings gaps — can usefully be combined with the group’s half-yearly reporting calendar.
How to Buy Fresenius Stock
- Choose a broker that gives access to XETRA or other German exchanges — compare the offers in our selection of the best online brokers.
- Open a PEA or a brokerage account: as a European issuer, the stock is eligible for the PEA; a standard brokerage account (CTO) remains the most flexible option.
- Fund the account in euros, with no currency conversion fees.
- Place your order on the FRE (FRE.DE) symbol, preferably as a limit order.
Trading hours
XETRA trades from 9:00 a.m. to 5:30 p.m. Paris time, Monday to Friday. The stock trades continuously and is part of Frankfurt’s DAX index.
Taxation
The German 26.375% withholding tax on dividends is limited to 15% under the tax treaty and can then be credited against the French 30% flat tax (PFU). The excess can be reclaimed through a German tax refund claim.
Fresenius Stock FAQ
Which exchange is Fresenius stock listed on?
On XETRA in Frankfurt, under the symbol FRE (FRE.DE line), in euros. The company is part of the DAX.
Does Fresenius pay a dividend?
Yes: €1.05 per share for 2025 according to StockAnalysis data, after €1.00, for a yield of around 2% to 3%.
Can Fresenius stock be held in a PEA?
Yes. The issuer is German, so the stock is eligible for the PEA as well as a standard brokerage account.
What is the Fresenius ISIN?
DE0005785604, for Fresenius SE & Co. KGaA — not to be confused with Fresenius Medical Care, a separate company listed separately.
What were Fresenius’s 2025 results?
Revenue of €22.9 billion (up 4.2%) and net income of €1.3 billion, compared with €0.5 billion in 2024, according to the consolidated accounts accessed on 10/27/2026.
Disclaimer: this content is for information only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not a reliable indicator of future results.
